stephenjmcd wrote: » Their own version of our HPRA says what they've received in the vials isn't the same as what the data has been submitted for.
stefanovich wrote: » This is being strongly refuted. Are you sure of your facts?
PhoenixParker wrote: » AZ has a 12 week dosing interval and we only started using it in early Feb. Up to yesterday's numbers we had at least 135k doses unused (205k doses used) The problem is cohort 4 is very slow to identify and get vaccinated and that's who the backlog of AZ is earmarked for at the moment. They should rocket through it in the mass vaccination centres for the 65-69 year olds but that's nearly 2 weeks away which is kinda frustrating since it's sitting there in the mean time.
stephenjmcd wrote: » Sure of my facts... feel free to give it a Google there, plenty of articles going around. By strongly refuted are you referencing that the reply was "enemies of Sputnik V in Slovakia".... yeah thats a strong rebuttal when someone says what you've supplied them isn't what they expected. "The Slovak State Institute for Drugs Control cannot adopt an expert stance on the ratio of benefits and risks surrounding the Sputnik V vaccine without sufficient evidence, and it is missing such evidence due to incomplete data from the manufacturer and the inconsistency of individual batches"
stefanovich wrote: » This is political.
stefanovich wrote: » You were implying that the Russian's supplied a fake vaccine. The other coalition members went nuts because he bypassed the EU. This vaccine has 98% efficacy.https://www.bbc.com/news/health-55900622 This is political.
stephenjmcd wrote: » What's in the vials is not what was submitted, its pretty straightforward to understand
stefanovich wrote: » Where did they say that?
astrofool wrote: » I think cohort 4 has been a bit of a mistake, we're just not digitised enough to roll out an ambiguous group quickly, would have been better to either just go with age based, or go with strict criteria that doesn't change (where that criteria is that you're identified by a certain date which would have avoided all the people who remembered they had a chronic illlness but haven't been getting treated for it)
is_that_so wrote: » They are still a vulnerable group and it's a sensible call, even if they miss some. They'll eventually pick up enough of them for it to be deemed complete. With Group 7 to follow there's a reasonable chance to get more of them anyway.
PhoenixParker wrote: » I think it should be done alongside at least one more big easy to find cohort, especially now that vaccine supply has arrived. I think the HSE have messed up a bit by not getting the 65-69 year olds registered last week and starting on them this week. It's not a huge delay in the grand scheme of things and maybe Cohorts 4's numbers this week will surprise me, but somehow I doubt it. (There's a large dollop of hindsight is 20:20 about this too).
1huge1 wrote: » My Dad (67, immunocompromised so presumably cohort 4) just got a call from his GP to expect ro receive a text for an appointment at the Radisson MVC in Limerick for today or tomorrow, such short notice but absolutely delighted all the same. He is more than happy to get the Astrazeneca vaccine bar the 12 week wait until the 2nd dose. I'm delighted anyway, my mum is a HCW and is getting her second AZ dose at the end of the month, big relief to have both parents vaccinated, even 1 dose reduces the risks massively.
Wolf359f wrote: » Pharmacists probably could have identified those in cohort 4 or 7 quicker based on prescriptions. Seems there's alot of paperwork involved with prescriptions until you get to the chemist when it's finally entered into a computer system (based on my experience only) They have the capability to identify, contact and administer a vaccine for those cohorts.
Wolf359f wrote: » It's based on eligible/adult population. So it would be a jump from about 10% to 19% I think. It's hard when they start using different % based on total population or adult population.
BERLIN (Reuters) - Global supply chains for making COVID-19 vaccines have been disrupted by U.S. restrictions, creating headaches for companies seeking to build production in Europe, according to one of the founders of Germany’s Curevac. Florian von der Muelbe said in a newspaper interview that he was hopeful Curevac’s vaccine candidate would win emergency European approval this quarter and confirmed a forecast that it would produce 300 million doses this year. He added, however, that vaccine makers seeking to build production in Europe were at a serious disadvantage because suppliers in the United States were required under the Defense Production Act to meet the needs of the home market first. “Global supply chains are disrupted,” von der Muelbe, now Curevac’s chief production officer, told the Rheinische Post in an interview published on Wednesday. “Be it chemicals, equipment, filters or hoses: U.S. manufacturers are obliged first to meet American demand, and that means we are slipping down the list.” Curevac is already producing its vaccine candidate, which is based on messenger RNA (mRNA) technology, at its plant in Tuebingen, Germany. It has just struck a partnership with Swiss contract manufacturer Celonic Group, adding to earlier alliances with Novartis AG, Bayer AG, Fareva, Wacker and Rentschler Biopharma SE.
stephenjmcd wrote: » What's in the vials is not what was submitted to the Lancet so no point in throwing in a link to the BBC which quotes it, its pretty straightforward to understand. Slovakia expected x in the vials they've looked at it and tested it and got y. What's so hard to understand?
speckle wrote: » I dont agree entirely... reading across the boards covid thread and having family friends neighbours in that cohort and people I know working with(ngos) or/treating them.. Some gps and hospital consultants and even ngo's have definitly been more organised than others in getting their lists together and in some instances personally contacting the patients/clients. Maybe they ones that havn't been able to needed more logistical/organisational help or extra staff especially GP's. ...
treatment: - included but not limited to Cyclophosphamide, Rituximab, Alemtuzumab, Cladribine or Ocrelizumab in the last 6 months
snotboogie wrote: » Is 850k still the goal for April? We have only done 80k in the first 6 days. That leaves us 770 to do in 24 days. That's an average of 32k per day. However there are 6 weekend days left. If we continue to average 5k per day on weekends we will need to average 41k per day on weekdays to reach 850k this month. Even if we up the weekends to 10k, we still need to average 40k on weekdays. Summary, the weekends are killing us at the moment and we will struggle to meet 850k in April at our current rate, especially if as I expect, we only hit 30k on Tuesday and Wednesday this week. 1.5 million total by the end of the month, or 600k total for April looks far more likely to me at the moment. We are going to either have to stop the weekend delays and match them to weekdays or start pulling out some 50k days to make up for the shortfall. I don't see either happening. A 50k day puts us at 1 per 100, that is globally notable and would put us top of the world in administration. Even 5 back to back 40k days would put us among the world's best.
Strazdas wrote: » I believe so. I've heard that the first supplies of the Johnson & Johnson vaccine are expected here in the next seven days (earlier than was anticipated).
Lucas Hood wrote: » Were only expecting 40000 from J&J in April according to Dept of Health.